İmmünoterapi ilişkili kolit

Özet

İmmün kontrol noktası inhibitörü kullanan ve karın ağrısı ya da ishal gelişen hastada kolit, tedaviye bağlı önemli bir bağırsak toksisitesidir. Kontrastlı BT tanıyı tek başına koymaz; duvar ve mukoza değişikliklerinin dağılımını gösterir, ayrıca dilatasyon, perforasyon ve eşlik eden başka akut karın nedenlerini araştırır. Yaygın kolit ile divertiküloz zeminindeki segmental tutulum farklı görünümler oluşturabilir. İskemik hasar, perforasyon veya ağır dilatasyonun atlanması acil komplikasyonun fark edilmesini geciktirebilir.

Faz ve pencere

Portal tanısal

İntravenöz kontrast sonrası kolon mukozasının belirginleşmesi, duvar kalınlaşması ve mezenterik vasa recta dolgunluğu değerlendirilir; yaygın tutulumda lümen sıvıyla dolu olabilir. Segmental tutulumda duvar değişikliği ve perikolik yağ çizgilenmesi sıklıkla divertiküloz bulunan kolon kesimine eşlik eder. Bu bulgular kolit paternini gösterir, ancak ilaca bağlı nedeni tek başına kanıtlamaz.

Önerilen pencereler: Batın (G 400 / M 50), Yumuşak doku (G 400 / M 40).

BT bulguları

• Yaygın duvar kalınlaşması — kolonun uzun kesimlerinde devamlı ya da atlamalı dağılım gösterir.
• Mukozal hiperenhansman — kontrastlı incelemede kolon mukozası kontrastlanma artışı gösterir; eşlik eden duvar kalınlaşması değerlendirilir.
• Mezenterik damar belirginliği — vasa recta dolgun veya kıvrımlı görünür; tedavi öncesi incelemeyle kıyas ipucu sağlar.
• Sıvı dolu kolon — lümen içeriği sıvı ağırlıklı ve kolon genişlemiş olabilir.
• Divertiküloz zemininde segmental kolit — divertiküllerin bulunduğu kolon kesiminde orta derecede duvar kalınlaşması, damar belirginliği ve perikolik yağ çizgilenmesi.
• İzole rektosigmoid tutulum — divertiküloz olmaksızın rektum ve sigmoidde mukozal belirginleşme; yağlı doku çizgilenmesi baskın bulgu olmayabilir.
• Perforasyon veya ağır dilatasyon — ekstraluminal serbest hava, duvar bütünlüğünde kesinti ya da belirgin kolon genişlemesi aranır.

Normalde

İyi distandü normal kolonda duvar ince ve düzgün, mukoza diğer bağırsak segmentlerine benzer biçimde kontrastlanmış, mezenterik damarlar belirgin tortiyöz değildir. Şüpheli kolon kesimini tedavi öncesi BT ve komşu sağlam segmentlerle karşılaştırın; kalınlaşmanın yaygın mı divertiküloz çevresinde sınırlı mı olduğunu ve perikolik yağ değişikliğini izleyin.

Ayırıcı tanı

Enfeksiyöz kolit

sıklıkla sağ kolon ağırlıklı, daha homojen duvar kontrastlanması gösterebilir; klinik ve dışkı testleriyle ayrım gerekir.

Ülseratif kolit

rektumdan başlayıp proksimale uzanan sürekli tutulum ve distal kolonda daha belirgin inflamasyon beklenir.

Crohn hastalığı

terminal ileum ve kolonda atlamalı, transmural tutulum; fistül, apse veya fibrofatty proliferasyon eşlik edebilir.

İskemik kolit

damar dağılımına uyan segmentte ödemli duvar, azalmış kontrastlanma veya ileri olguda pnömatozis görülebilir.

Aktif divertiküloz

semptomların nispeten hafif olması ve dışkıda bakteriyel patojen ya da lökosit bulunmaması, segmental immün kolit ile karşılaştırıldığında ayırt edici bulgu sağlar.

Tuzaklar

• BT’de kolit görünümü immün toksisiteye özgü değildir; enfeksiyon, inflamatuvar bağırsak hastalığı ve iskemi klinik bağlamla dışlanmalıdır.
• Divertiküloz zeminindeki segmental değişiklikler — semptomların hafif seyretmesi ve dışkı patojen/lökosit testlerinin negatif olması, segmental immün kolitin aktif divertikülozdan ayrımında rehberlik eder.
• Pnömatozis, halo veya target görünümü immün kolite özgü kabul edilmemeli; başka kolit nedenleri ve iskemi de düşünülmelidir.
• BT’de belirgin anormallik görülmemesi semptomatik immün koliti dışlamaz; görüntüleme tanı için endoskopi ve klinik değerlendirmeye alternatif değildir.

Kendini dene

1. İmmün kontrol noktası inhibitörü kullanan hastada dışkı etken incelemeleri negatif; yaygın kolon duvar kalınlaşması ve mezenterik damar belirginliği görülüyor. BT bulguları ve tedavi öyküsü hangi tanıyı destekler?

   • İmmünoterapi ilişkili kolit
   • İskemik kolit
   • Ülseratif kolit
   • Enfeksiyöz kolit
   Cevabı göster

   İmmünoterapi ilişkili kolit. Yaygın duvar kalınlaşması, mukozal hiperenhansman ve mezenterik damar belirginliği immün ilişkili yaygın kolit paternini destekler. Negatif dışkı etken incelemesi ve tedavi öyküsü olasılığı artırır; BT tek başına ilaca bağlı nedeni kanıtlamaz. İskemi damar dağılımına uyan tutulum ve azalmış kontrastlanmayla, ülseratif kolit sürekli distal tutulumla; enfeksiyon klinik ve mikrobiyolojik verilerle değerlendirilir.

2. İmmün kontrol noktası inhibitörü kullanan, dışkı patojen incelemesi negatif hastada divertikülozlu sigmoid kesimde orta derecede kalınlaşma, perikolik yağ reaksiyonu ve damar dolgunluğu var; inflame divertikül seçilmiyor. En uygun patern hangisidir?

   • Crohn koliti
   • Segmental immün kolit
   • Akut mezenter iskemi
   • Ülseratif kolit
   Cevabı göster

   Segmental immün kolit. Divertiküloz içeren sınırlı kolon kesimindeki orta derecede kalınlaşma, perikolik yağ çizgilenmesi ve damar belirginliği immün ilişkili segmental kolit (SCAD-benzeri) paternini destekler. Inflame divertikülün gösterilmemesi akut divertikülit lehine kanıtı azaltır; Crohn’da atlamalı transmural hastalık ve terminal ileum tutulumu, iskemide damar dağılımı/perfüzyon bozukluğu, ülseratif kolitte sürekli distal tutulum aranır.

İlgili konular

• İnfeksiyöz kolit
• Ülseratif kolit

Kaynaklar

Bu sayfadaki 39 cümle ve 2 quiz sorusu aşağıdaki kaynaklardan alıntılarla tek tek karşılaştırıldı; 2 cümle bu karşılaştırmada düzeltildi (2026-10-09).

1. Imaging of Adverse Events Related to Checkpoint Inhibitor Therapypmc.ncbi.nlm.nih.gov
2. Gastrointestinal adverse events of immunotherapypmc.ncbi.nlm.nih.gov
3. Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis.pubmed.ncbi.nlm.nih.gov
4. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.pubmed.ncbi.nlm.nih.gov
5. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients.pubmed.ncbi.nlm.nih.gov
6. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.pubmed.ncbi.nlm.nih.gov
7. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.pubmed.ncbi.nlm.nih.gov
8. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.pubmed.ncbi.nlm.nih.gov
9. Ipilimumab-induced colitis on FDG PET/CT.pubmed.ncbi.nlm.nih.gov
10. [Adverse events of immune checkpoint inhibitors].pubmed.ncbi.nlm.nih.gov
11. Image intensity histograms as imaging biomarkers: application to immune-related colitis.pubmed.ncbi.nlm.nih.gov
12. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management.pubmed.ncbi.nlm.nih.gov
13. Drug-induced Pancreatic Atrophy ("The Vanishing Pancreas").pubmed.ncbi.nlm.nih.gov
14. [Can nivolumab be used safely in idiopathic pulmonary fibrosis?].pubmed.ncbi.nlm.nih.gov
15. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.pubmed.ncbi.nlm.nih.gov
16. Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.pubmed.ncbi.nlm.nih.gov
17. Probable everolimus-associated severe colitis with hematochezia in a patient with metastatic hormone receptor-positive, HER2-negative breast cancer: a case report.pubmed.ncbi.nlm.nih.gov
18. Immune checkpoint inhibitor-related intestinal pseudo-obstruction and multisystem immune-related adverse events in a post-gastrectomy patient: a case report and literature review.pubmed.ncbi.nlm.nih.gov
19. Immune Checkpoint Inhibitor Esophagitis: Clinical and Endoscopic Presentation, Treatment Outcomes, and Complications.pubmed.ncbi.nlm.nih.gov
20. A Case of Fulminant Immune-Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma.pubmed.ncbi.nlm.nih.gov
21. Myokine-mediated mechanisms of immune checkpoint inhibitors-associated colorectal injury and repair in rectal cancer.pubmed.ncbi.nlm.nih.gov
22. Segmental Colitis Associated with Diverticulosis: Status Quo.pubmed.ncbi.nlm.nih.gov
23. Imaging Findings of Complications of New Anticancer Drugs.pubmed.ncbi.nlm.nih.gov
24. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.pubmed.ncbi.nlm.nih.gov
25. Idiopathic mesenteric phlebosclerosis: A case report.pubmed.ncbi.nlm.nih.gov
26. Hematemesis resulting from mesenteric venous thrombosis: A case report.pubmed.ncbi.nlm.nih.gov
27. The Importance of Magnetic Resonance Enterography in Monitoring Inflammatory Bowel Disease: A Review of Clinical Significance and Current Challenges.pubmed.ncbi.nlm.nih.gov
28. Analysis of clinical characteristics of 117 cases of ischemic colitis.pubmed.ncbi.nlm.nih.gov
29. Diagnostic Role of Multi-Detector Computed Tomography in Acute Mesenteric Ischemia.pubmed.ncbi.nlm.nih.gov
30. The Role of CT-Angiography in the Acute Gastrointestinal Bleeding: A Pictorial Essay of Active and Obscure Findings.pubmed.ncbi.nlm.nih.gov
31. A Case of Amyloid Light-Chain Amyloidosis Presenting as Colitis.pubmed.ncbi.nlm.nih.gov
32. When Pancreatitis Strikes the Colon: A Rare Case Report of Sigmoid Perforation.pubmed.ncbi.nlm.nih.gov
33. Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach.pubmed.ncbi.nlm.nih.gov
34. Hematological Toxicities in the Modern Era of Melanoma Therapy.pubmed.ncbi.nlm.nih.gov
35. A case report of a rare intrahepatic cholangiocarcinoma with rectal metastasis.pubmed.ncbi.nlm.nih.gov
36. Gastrointestinal adverse events of immunotherapy.pubmed.ncbi.nlm.nih.gov
37. The Role of Imaging in Inflammatory Bowel Diseases: From Diagnosis to Individualized Therapy.pubmed.ncbi.nlm.nih.gov
38. Comprehensive Imaging Evaluation and Staging of Crohn's Disease: When and Why to Use Intestinal Ultrasound, MRE, or CTE: Current Guidelines and Future Directions.pubmed.ncbi.nlm.nih.gov
39. Long-term safety and effectiveness of the "OptEase" vena cava filter.pubmed.ncbi.nlm.nih.gov
40. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.pubmed.ncbi.nlm.nih.gov
41. Chemotherapy-induced bowel ischemia: diagnostic imaging overview.pubmed.ncbi.nlm.nih.gov
42. Consensus guidelines for the use and interpretation of angiogenesis assays.pubmed.ncbi.nlm.nih.gov
43. Pneumatosis Intestinalis Secondary to Appendicitis: What Do We Know?pubmed.ncbi.nlm.nih.gov
44. Colonic Volvulus.pubmed.ncbi.nlm.nih.gov
45. A Study on the Spectrum of Imaging Findings of Post-ERCP-Specific Complications: A Retrospective Descriptive Study.pubmed.ncbi.nlm.nih.gov
46. Integrating Intestinal Ultrasound in the Personalized Management of IBD.pubmed.ncbi.nlm.nih.gov
47. The Many Faces of the Angry Peritoneum.pubmed.ncbi.nlm.nih.gov
48. Gastrointestinal Ultrasound: Measurements and Normal Findings - What Do You Need to Know?pubmed.ncbi.nlm.nih.gov
49. Is 18 F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons.pubmed.ncbi.nlm.nih.gov
50. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.pubmed.ncbi.nlm.nih.gov
51. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.pubmed.ncbi.nlm.nih.gov
52. Mass-Forming NSAID-Associated Colopathy Mimicking Right-Sided Colon Cancer: A Case Report.pubmed.ncbi.nlm.nih.gov
53. When It Is Not NEC: Recognizing Mimics of Necrotizing Enterocolitis in Preterm Infants.pubmed.ncbi.nlm.nih.gov
54. Recent advances in the diagnosis and management of amoebiasis.pubmed.ncbi.nlm.nih.gov
55. Apical Periodontitis May Exacerbate Ulcerative Colitis via Neutrophil Extracellular Trap-Mediated Systemic Inflammation and Intestinal Barrier Disruption in Mice.pubmed.ncbi.nlm.nih.gov
56. Current Status of Diagnosis and Treatment of Cap Polyposis: Insights From Chinese Studies and Comparative Analysis with Japanese Cases.pubmed.ncbi.nlm.nih.gov
57. Incidental findings in female pelvis MRI performed for gynaecological malignancies.pubmed.ncbi.nlm.nih.gov
58. The Diagnostic Challenge of Crohn's Disease With Initial Duodenal Involvement: Two Cases and Literature Review.pubmed.ncbi.nlm.nih.gov
59. The Overlap Between Crohn's Disease and Intestinal Tuberculosis: A Never-Ending Story.pubmed.ncbi.nlm.nih.gov
60. Endoscopic Skipping, Stricturing, and Penetrating Complications in Crohn's Disease on Tandem Ileo-colonoscopy and Cross-sectional Imaging: A Retrospective Cohort Study.pubmed.ncbi.nlm.nih.gov
61. Computed tomography findings and surgical outcomes in acute mesenteric ischemia: a retrospective single-center cohort study.pubmed.ncbi.nlm.nih.gov
62. Gastrointestinal complications of cocaine use: a narrative literature review.pubmed.ncbi.nlm.nih.gov
63. Mesenteric Ischemia: A Comprehensive Review of the Role of Radiology in Diagnosis.pubmed.ncbi.nlm.nih.gov
64. Perforation in a patient with stercoral colitis and diverticulosis: who did it?pubmed.ncbi.nlm.nih.gov
65. Immune checkpoint inhibitor-related pancreatitis: a comprehensive review of epidemiology, pathophysiology, and management.pubmed.ncbi.nlm.nih.gov
66. A Rare Case of Severe Disseminated Pyoderma Gangrenosum of the Upper Body With Concurrent Nasopharyngeal and Inferior Orbital Wall Necrosis.pubmed.ncbi.nlm.nih.gov
67. Trends and Outcomes in Acute Colonic Diverticulitis: A Single-Center Three-Year Retrospective Cohort Study From Greece.pubmed.ncbi.nlm.nih.gov
68. Small Bowel Diverticulosis and COVID-19: Awareness Is the Key: A Case Series and Review of the Literature.pubmed.ncbi.nlm.nih.gov
69. Pneumatosis intestinalis revisited: associated imaging findings, clinical correlation, management, risk stratification and future perspectives.pubmed.ncbi.nlm.nih.gov
70. The Usefulness and Limitations of Radiologic Findings for Diagnosis of Infectious Diseases: A Call for Antimicrobial Stewardship.pubmed.ncbi.nlm.nih.gov
71. POCUS for acute abdominal pain: practical scan protocols on gastrointestinal diseases and an evidence review.pubmed.ncbi.nlm.nih.gov
72. Organ preservation after neoadjuvant immunotherapy in mismatch repair-deficient colorectal cancer: response assessment, watch-and-wait, and salvage surgery.pubmed.ncbi.nlm.nih.gov
73. Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.pubmed.ncbi.nlm.nih.gov
74. Synergistic neoadjuvant radioimmunotherapy in locally advanced rectal cancer: mechanisms of pathologic response and the shift toward organ preservation.pubmed.ncbi.nlm.nih.gov
75. Iatrogenic perforation of a sigmoid diverticulum following diagnostic colonoscopy.pubmed.ncbi.nlm.nih.gov
76. Perforated Ileal Diverticulitis Presenting With Acute Peritonitis in an Elderly Patient: A Case Report.pubmed.ncbi.nlm.nih.gov
77. Acute abdomen secondary to perforated jejunal diverticulitis: an unusual clinical presentation - case report.pubmed.ncbi.nlm.nih.gov
78. Visual theranostic oral nanozymes for IBD from principles to preclinical design.pubmed.ncbi.nlm.nih.gov
79. Role of multidetector computed tomography in patients with acute infectious colitis.pubmed.ncbi.nlm.nih.gov
80. Gastrointestinal perforation: clinical and MDCT clues for identification of aetiology.pubmed.ncbi.nlm.nih.gov
81. Risk Factors Associated with Intestinal Strangulation in Patients with Adhesive Small Bowel Obstruction: A Retrospective Analysis of 951 Cases.pubmed.ncbi.nlm.nih.gov
82. Acute toxic megacolon in visceral myopathy: A rare and challenging case report with literature review.pubmed.ncbi.nlm.nih.gov
83. Special Issue: EACR 2026 Congress: Innovative Cancer Science, 8-11 June 2026.pubmed.ncbi.nlm.nih.gov
84. Nontuberculous mycobacterial infections in the setting of immune checkpoint inhibitor therapy: A case series.pubmed.ncbi.nlm.nih.gov
85. Cytotoxic T-Lymphocyte-Associated Protein 4 Deficiency Colitis Masked by Recurrent Cytomegalovirus Colitis Successfully Treated With Vedolizumab.pubmed.ncbi.nlm.nih.gov
86. Review of COVID-19, part 1: Abdominal manifestations in adults and multisystem inflammatory syndrome in children.pubmed.ncbi.nlm.nih.gov
87. Multisystem Imaging Manifestations of COVID-19, Part 2: From Cardiac Complications to Pediatric Manifestations.pubmed.ncbi.nlm.nih.gov
88. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.pubmed.ncbi.nlm.nih.gov
89. Soil-derived microbiota induces T regulatory cells and protect against mouse colitis, metabolic disease, and sepsis.pubmed.ncbi.nlm.nih.gov
90. Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies.pubmed.ncbi.nlm.nih.gov
91. Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis.pubmed.ncbi.nlm.nih.gov
92. International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.pubmed.ncbi.nlm.nih.gov
93. EACR 2025 Congress: Innovative Cancer Science, 16-19 June 2025.pubmed.ncbi.nlm.nih.gov
94. Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies.pubmed.ncbi.nlm.nih.gov
95. Colonic diverticular disease.pubmed.ncbi.nlm.nih.gov
96. Role of magnetic resonance in bowel pathologies: Beyond inflammatory bowel disease.pubmed.ncbi.nlm.nih.gov
97. Rapid Progressive Liver Atrophy During Immune Checkpoint Inhibitor Hepatitis: Imaging Perspectives Beyond Aminotransferase Elevation.pubmed.ncbi.nlm.nih.gov
98. Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities.pubmed.ncbi.nlm.nih.gov
99. Vedolizumab: Beyond Inflammatory Bowel Disease.pubmed.ncbi.nlm.nih.gov
100. Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE.pubmed.ncbi.nlm.nih.gov
101. Management of acute severe ulcerative colitis-an update for generalist and specialist clinicians.pubmed.ncbi.nlm.nih.gov
102. Faecal Calprotectin: A Non-Invasive Marker for Diagnosing and Monitoring Acute Diverticulitis.pubmed.ncbi.nlm.nih.gov
103. Utility of Colonoscopy After Acute Colonic Diverticulitis.pubmed.ncbi.nlm.nih.gov
104. Imaging of ectopic gastric mucosa in Meckel's diverticulum: A case report and literature review.pubmed.ncbi.nlm.nih.gov
105. Complicated Jejunal Diverticulosis as a Rare Cause of Small Bowel Perforation in an Immunocompromised Patient: A Case Report.pubmed.ncbi.nlm.nih.gov
106. A Rare Case of Giant Meckel's Diverticulum in an Adult: Diagnostic and Therapeutic Challenges.pubmed.ncbi.nlm.nih.gov

Eğitim amaçlıdır; hasta başında tanı ve tedavi kararının yerine geçmez. İçerik yapay zekâ destekli bir süreçle güncel literatüre göre cümle cümle kaynaklarla karşılaştırıldı, ancak uzman radyolog incelemesinden geçmedi. Klinik kararlarda güncel kılavuzları, kurum protokollerini ve radyoloji raporunu esas alın.